Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or delay diabetes in UCD-T2DM rats, a model of polygenic obese type 2 diabetes, was investigated. RESEARCH DESIGN AND METHODS: At 2 months of age, male rats were divided into three groups: control, food-restricted, and liraglutide. Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily. Restricted rats were food restricted to equalize body weights to liraglutide-treated rats. Half of the animals were followed until diabetes onset, whereas the other half of the animals were killed at 6.5 months of age for tissue collection. RESULTS: Before diabetes onset energy intake, body weight, adiposity, and liver triglyceride content were higher in control animals compared with restricted and liraglutide-treated rats. Energy-restricted animals had lower food intake than liraglutide-treated animals to maintain the same body weights, suggesting that liraglutide increases energy expenditure. Liraglutide treatment delayed diabetes onset by 4.1 ± 0.8 months compared with control (P < 0.0001) and by 1.3 ± 0.8 months compared with restricted animals (P < 0.05). Up to 6 months of age, energy restriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared with control animals. In contrast, liraglutide-treated animals exhibited lower fasting plasma insulin, glucagon, and triglycerides compared with both control and restricted animals. Furthermore, energy-restricted and liraglutide-treated animals exhibited more normal islet morphology. CONCLUSIONS: Liraglutide treatment delays the development of diabetes in UCD-T2DM rats by reducing energy intake and body weight, and by improving insulin sensitivity, improving lipid profiles, and maintaining islet morphology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 4×
“This GLP-1– mediated improvement of -cell function is in agreement with previous studies (1), and it is consistent with in2 3 4 5 6 4 5 6 7 8 9 10 11”
BackgroundResultInfluentialBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 signaling increases satiety (6,7) and slows gastric motility and secretion, further contributing to a reduction in food intake (8).”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Morino, K., Petersen, K. F., & Shulman, G. I. (2006) · Diabetes · doi:10.2337/db06-s002 · Cited by 853 · cited 1×
“Reductions of circulating and ectopic TG content are likely to contribute to the improvement in insulin sensitivity, as deposition of TG in the liver impairs insulin signaling through the production of lipid metabolites that reduce insulin receptor substrate-2 tyrosine phosphorylation (37).”
BackgroundZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 4×
“Thus, one method currently being pursued for the therapeutic targeting of GLP-1 is production of GLP-1 analogs that are resistant to degradation by DPP-IV.”
BackgroundInfluential
Cited by
Animal models of obesity and diabetes mellitus
Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 832
Self-citationThe Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031882 · Cited by 465
Laboratory animals as surrogate models of human obesity
Nilsson, C., Raun, K., Yan, F.-F., Larsen, M. O., & Tang-Christensen, M. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.203 · Cited by 275
Self-citationSourris, K. C., Ding, Y., Maxwell, S. S., Al-sharea, A., Kantharidis, P., Mohan, M., Rosado, C. J., Penfold, S. A., Haase, C., Xu, Y., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.029 · Cited by 143
Self-citationGotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
Self-citationNikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
Rodgers, M., Migdal, A. L., Rodríguez, T. G., Chen, Z.-Z., Nath, A. K., Gerszten, R. E., Kasid, N., Toschi, E., Tripaldi, J., Heineman, B., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.742873 · Cited by 24
“Additionally, the present study did not show a significant change in fasting triglycerides among those treated with exenatide, including high responders, although several human and rodent studies have reported significant decreases in triglycerides following treatment with GLP1RA (24, 25).”
ResultInfluential
Metadata
- Authors
- Cummings, B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson, C., Sams, A., Knudsen, L. B., Raun, K., & Havel, P. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-07-09
- Volume
- 59
- Issue
- 10
- Pages
- 2653-2661
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2170401510
- Cited by
- 72
- References
- 14
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.